Amicogen Inc

Amicogen Inc operates with a market price of 1,715 KRW and a market capitalization of 95.23 billion KRW, with a price-to-book ratio of 1.01 and a price-to-tangible-book ratio of 1.01. The company's enterprise value to EBITDA is -9.43, indicating a negative earnings profile, while the enterprise value to revenue is 4.62. The company's return on equity is -31.68%, and return on assets is -12.92%, both significantly below the industry median for profitability. The company's capital structure is highly leveraged, with a debt-to-equity ratio of 1.11 and a current ratio of 0.47, suggesting limited short-term liquidity. The company's operating cash flow is negative at -25.5 billion KRW, and free cash flow is also negative at -24.5 billion KRW, indicating a lack of cash generation from operations. The company's long-term debt of 104.79 billion KRW is a significant portion of its total liabilities, which stand at 137.30 billion KRW. Amicogen Inc's profitability is underperforming relative to industry standards, with a net loss of 29.96 billion KRW and an operating loss of 20.54 billion KRW. The company's gross profit of 5.51 billion KRW is minimal compared to its revenue of 41.98 billion KRW, indicating high cost pressures. The company's return on equity and return on assets are both negative, suggesting poor capital efficiency and asset utilization. The company's revenue is derived from the sale of enzymes, bio new materials, and healthcare food, with no disclosed segment breakdown. The company operates in both domestic and overseas markets, but the geographic distribution of revenue is not specified. The company's reliance on a limited product portfolio and lack of geographic diversification may pose concentration risks. Amicogen Inc's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections. The company's operating and net losses suggest a lack of profitability, and the negative cash flows indicate a need for external financing. The company's capital expenditures of -3.77 billion KRW are minimal, suggesting limited investment in growth initiatives. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The key risk flag is the negative net cash position after subtracting total debt, indicating a potential liquidity crunch. The company's high debt levels and negative cash flows may necessitate further financing, which could lead to dilution or increased interest costs. Recent events and filings do not provide specific details on the company's strategic initiatives or financial performance. The company's 10-K filings and other disclosures are not publicly available in the provided data, limiting the ability to assess recent developments or management commentary.